The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

Inclusion Criteria:

1. Participant and parent (or guardian) are able and willing to provide consent

2. Participant and parent (or guardian) ensure to attend required study visits andadhere to participant requirements

3. Parent or guardian understands and accepts random allocation of grouping, and thatparticipant and parent (or guardian) will not be told which group participant isallocated to

4. Participant willing to wear the study spectacles lens for a minimum of 12 hours perday for the duration of the study

5. Age at time of parent or guardian consent and participant assent: 7 - 13 years old

6. Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye.

7. Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye

8. Cycloplegic autorefraction anisometropia of 1.50 D or less

9. Monocular best corrected distance visual acuity (BCDVA) equal to or better thanlogMAR 0.00 in each eye.

Exclusion Criteria:

1. Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide orcyclopentolate eye drops

2. Any ocular and systemic abnormalities might be expected to affect visual functionsor refractive development

3. (a) Have received treatment of myopic control pharmaceutical medication (e.g.,atropine) or light fundus illuminance therapy (e.g., repeated red light therapy)within 6 months prior to entry into this study. (b) Have received treatment ofmyopia control such as contact lenses, orthokeratology lenses etc., progressiveaddition lenses, bifocal lenses, within 3 months. (c) Have received treatment ofmyopia control such as defocus spectacle lenses (difference between both eye'snon-cycloplegic autorefraction and lens-meter results of the respective lenses areequal or less than 0.50 D SER) etc. within one month prior to entry into this study.

4. Participant with clinically significant strabismus (including intermittent tropia)

5. Medical history of binocular vision abnormalities

6. Participant with amblyopia

7. Participation in a clinical trial within 30 days prior to entry into this study orduring participation

8. Previous intraocular surgery

9. Participant who, in the judgment of the Investigator, presence of any emotional,physiologic, or anatomical condition which may preclude participation in this studyor provide an inappropriate landscape for the intended study treatment.

10. Any medical treatment or medication which might have an influence on vision orinterfere with study assessments

11. Pathological myopia (myopia that leads to structural changes in the posteriorsegment of the eye including posterior staphyloma, myopic maculopathy, and highmyopia-associated optic neuropathy)